País: Regne Unit
Idioma: anglès
Font: myHealthbox
pemetrexed
Caduceus Pharma Ltd.
L01BA04
pemetrexed
25mg
Concentrate for solution for infusion
intravenous infusion
1 x 4 ml vial (100 mg/4 ml) 1 x 20 ml vial (500 mg/20 ml) 1 x 40 ml vial (1000 mg/ 40 ml)
POM - Prescription Only Medicine
Actavis Italy
Folic acid analogues
Malignant pleural mesothelioma Pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology Pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Authorised
2015-12-09
! READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, nurse or pharmacist. • If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • The full name of this medicine is Pemetrexed 25mg/ml Concentrate for Solution for Infusion but within the leaflet it will be referred to as Pemetrexed. WHAT IS IN THIS LEAFLET: 1. What Pemetrexed is and what it is used for 2. What you need to know before you use Pemetrexed 3. How to use Pemetrexed 4. Possible side effects 5. How to store Pemetrexed 6. Contents of the pack and other information 1. WHAT PEMETREXED IS AND WHAT IT IS USED FOR Pemetrexed is a medicine used in the treatment of cancer. It contains the active substance pemetrexed. Pemetrexed belongs to a group of medicines known as folic acid analogues and disrupts processes that are essential for cells to divide. Pemetrexed is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy. Pemetrexed is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer. Pemetrexed can be prescribed to you if you have lung cancer at an advanced stage if your disease has responded to treatment or it remains largely unchanged after initial chemotherapy. Pemetrexed is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE PEMETREXED DO NOT USE PEMETREXED • if you are aller Llegiu el document complet
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w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legiu el document complet